Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
1.31
Nov 16 • 3:59 PM ET Dollar change0.00 Percentage change(0.00%)
Index
-
Market Cap
42.16M
Enterprise Value
47.55M
Income
-10.60M
Sales
14.22M
Book/sh
-0.48
Cash/sh
0.35
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
65
IPO
Apr 06, 2021
P/E
-
Forward P/E
-
PEG
-
P/S
2.96
P/B
-
P/C
3.75
P/FCF
-
EV/EBITDA
-
EV/Sales
3.34
Quick Ratio
0.59
Current Ratio
0.63
Debt/Eq
-
LT Debt/Eq
-
Option/Short
No / Yes
EPS (ttm)
-0.33
EPS next Y
-0.28
EPS next Q
-0.13
EPS this Y
-60.92%
EPS next Y
40.00%
EPS next 5Y
-0.00%
EPS past 3/5Y
-8.80% -
Sales past 3/5Y
-8.16% -
EPS Y/Y TTM
55.03%
Sales Y/Y TTM
-38.62%
EPS Q/Q
15.85%
Sales Q/Q
-24.68%
Insider Own
16.24%
Insider Trans
0.00%
Inst Own
10.31%
Inst Trans
7.59%
ROA
-66.56%
ROE
-
ROIC
-
Gross Margin
38.32%
Oper. Margin
-89.61%
Profit Margin
-74.56%
SMA20
-11.22%
SMA50
-15.74%
SMA200
-22.42%
Trades
Shs Outstand
32.18M
Shs Float
26.96M
52W High
2.97 -55.89%
52W Low
1.18 11.02%
Volatility
9.52% 6.01%
ATR (14)
0.10
RSI (14)
34.38
Beta
1.28
Rel Volume
0.00
Avg Volume
133.95K
Volume
0
Perf Week
-14.38%
Perf Month
-13.25%
Perf Quarter
-18.63%
Perf Half Y
-41.52%
Perf YTD
-7.75%
Perf Year
-13.82%
Perf 3Y
-51.48%
Perf 5Y
-86.70%
Perf 10Y
-
Prev Close
1.31
Price
1.31
Change %
0.00%
Consensus
Strong Buy
Avg. Price Target
$5.11
Implied Upside
+290.1%
Analysts1incl. previous ratings
Rating Distribution1 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jan 23, 2024Initiated
BBTIG Research
Buy$4+205.3%
Spectral AI, Inc. is a predictive artificial intelligence company. It focuses on medical diagnostics for accurate treatment decisions in wound care for burn, DFU, and future clinical applications. Its DeepView platform is a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound's healing potential prior to treatment or other medical intervention. The company was founded by John Michael DiMaio and Wen Sheng Fan on November 17, 2020 and is headquartered in Dallas, TX.
Founder & ChairmanDr. John Michael DiMaio M.D.
CEO & Corporate SecretaryMr. Vincent Stanley Capone Esq.
Chief Operating OfficerMr. Stanley Micek
Head of Regulatory Affairs & Clinical TrialsMs. Allison Kumar
General ManagerMr. Louis Percoco